Assessment of Nutritional Status in Cancer – The Relationship Between Body Composition and Pharmacokinetics

ISSN: 1875-5992 (Online)
ISSN: 1871-5206 (Print)

Volume 17, 14 Issues, 2017

Download PDF Flyer

Anti-Cancer Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Cancer Agents

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 27th of 59 in Chemistry, Medicinal

Submit Abstracts Online Submit Manuscripts Online

Michelle Prudhomme
Institut de Chimie de Clermont-Ferrand
Université Clermont Auvergne

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.722
5 - Year: 2.849

Assessment of Nutritional Status in Cancer – The Relationship Between Body Composition and Pharmacokinetics

Anti-Cancer Agents in Medicinal Chemistry, 13(8): 1197-1203.

Author(s): Carla M. M. Prado, Yara L. M. Maia, Michael Ormsbee, Michael B. Sawyer and Vickie E Baracos.

Affiliation: Department of Nutrition, Food and Exercise Sciences, The Florida State University, 120 Convocation Way, PO Box 3061493, Tallahassee, FL 32306-1493.


Several nutritional assessment tools have been used in oncology settings to monitor nutritional status and its associated prognostic significance. Body composition is fundamental for the assessment of nutritional status. Recently, the use of accurate and precise body composition tools has significantly added to the value of nutritional assessment in this clinical setting. Computerized tomography (CT) is an example of a technique which provides state-of-the-art assessment of body composition. With use of CT images, a great variability in body composition of cancer patients has been identified even in people with identical body weight or body mass index. Severe muscle depletion (sarcopenia) has emerged as a prevalent body composition phenotype which is predictive of poor functional status, shorter time to tumor progression, shorter survival, and higher incidence of dose-limiting toxicity. Variability in body composition of cancer patients may be a source of disparities in the metabolism of cytotoxic agents. Future clinical trials investigating dose reductions in patients with sarcopenia and dose-escalating studies based on pre-treatment body composition assessment have the potential to alter cancer treatment paradigms.


Body composition, cancer, cancer prognosis, chemotherapy treatment, nutritional assessment, nutritional status, pharmacokinetics.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 13
Issue Number: 8
First Page: 1197
Last Page: 1203
Page Count: 7
DOI: 10.2174/18715206113139990322
Price: $58

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science